Acute Doxorubicin Cardiotoxicity

Hayek, Emil; Speakman, Eric; Rehmus, Esther H.

doi:10.1056/nejm200506093522321

Cited by 73 publications

(42 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The proposed mechanisms of arrhythmia generally focus on the inhibition of Na + -Ca 2+ exchange with prolongation of the myocyte action potential, damage from reactive oxygen species, or myocardial necrosis [4,12]. Animal studies suggest that β-blockade may prevent these electrophysiological changes, with limited evidence in humans suggesting a role of β-blockers in patients undergoing therapy with anthracyclines [13,14].…”

Section: Discussionmentioning

confidence: 99%

Arrhythmia and Electrophysiological Effects of Chemotherapy: A Review

Markman

Nazarian²

2016

Oncology

View full text Add to dashboard Cite

Importance: Cardiotoxicity is an important limiting factor in the use of antineoplastic agents. The risk of arrhythmia and the electrophysiological effects of these agents are poorly characterized though increasing evidence suggests a high prevalence of complications. Observations: Patients with substantial cardiovascular risk factors are often excluded from clinical trials, while the aging population of patients actually receiving therapies may have an underlying arrhythmogenic substrate due to comorbidities. Risk stratification of patients before the selection of a therapeutic regimen is essential. Given the regular use of combination therapies, the potential for arrhythmia of each agent must be fully understood. Despite limited data and understanding in clinical practice, decisions on whether to initiate specific therapies in high-risk patients and how to manage the associated complications are made regularly. Conclusions and Relevance: This review describes the observed arrhythmias and proposed mechanisms for several major classes of antineoplastic agents. It also provides recommendations for risk stratification, monitoring, prophylaxis, and therapy, emphasizing the need for a collaborative relationship between oncologists and cardiologists and areas for future research.

show abstract

Section: Discussionmentioning

confidence: 99%

Arrhythmia and Electrophysiological Effects of Chemotherapy: A Review

Markman

Nazarian²

2016

Oncology

View full text Add to dashboard Cite

show abstract

“…Their main adverse effect is cardiotoxicity. [110][111][112][113][114] Acute toxicity are usually reversible and nonfatal, such as hypotension, tachycardia, and arrhythmias. However, late-onset cardiotoxicity causes lethal congestive heart failure.…”

Section: Liposomesmentioning

confidence: 99%

Applications of Nanoparticles for Anticancer Drug Delivery: A Review

Zhu¹,

Liao²

2015

j nanosci nanotechnol

129

View full text Add to dashboard Cite

Biodegradable nanometer-sized particles have novel structural and physical properties that are attracting great interests from pharmaceuticals for the targeted delivery of anticancer drugs and imaging contrast agents. These smart nanoparticles are designed to ferry chemotherapeutic agents or therapeutic genes into malignant cells while sparing healthy cells. In this review, we describe currently clinically used chemotherapeutics in nanoparticle formulation and discuss the current status of nanoparticles developed as targeting delivery systems for anticancer drugs, with emphasis on formulations of micelles, liposome, polymeric nanoparticles, gold nanoparticle dendrimers, and bionanocapsules.

show abstract

“…Its major cumulative dose-limiting toxicity is congestive heart failure, typically insidious in onset after chronic anthracycline treatment, particularly with cumulative doses in excess of 500 mg/m 2 [2]. Rarely, acute left ventricular failure has been described within a week of anthracycline administration and is usually fatal [3][4][5]. The development of acute heart failure does not appear to be dose related, however, the total dose administered during a day or course of treatment may affect late cardiotoxicity [6].…”

Section: Introductionmentioning

confidence: 99%

Acute Heart Failure in a Patient with Acute Myeloid Leukemia following Daunorubicin Treatment: a Case Report

Fasan¹

2015

J Leuk

View full text Add to dashboard Cite

Heart failure following anthracycline treatment is usually chronic, irreversible, and related to life time dose. We present a patient with Acute Myeloid Leukemia (AML) who developed Heart failure soon after dose intensified treatment with daunorubicin, with a decrease in Ejection Fraction (EF) from 60% to as low as 10% six months after initial treatment. The patient was managed medically, his EF increased to greater than 50%. With this improvement in EF the patient was treated with reinduction chemotherapy and proceeded to hematopoietic stem cell transplantation. Following transplantation, the patient again developed heart failure, which contributed to his death. While anthracycline dose intensification can be effective in the treatment of AML, there is a risk of heart failure which requires further study.

show abstract

Acute Doxorubicin Cardiotoxicity

Cited by 73 publications

References 3 publications

Arrhythmia and Electrophysiological Effects of Chemotherapy: A Review

Arrhythmia and Electrophysiological Effects of Chemotherapy: A Review

Applications of Nanoparticles for Anticancer Drug Delivery: A Review

Acute Heart Failure in a Patient with Acute Myeloid Leukemia following Daunorubicin Treatment: a Case Report

Contact Info

Product

Resources

About